POINT Biopharma Global Inc. (PNT) Stock Analysis
DELISTED 2023
What happened to POINT Biopharma Global Inc. (PNT) stock?
POINT Biopharma Global Inc. (PNT) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- December 2023
- Last recorded price (historical):
- $12.50 (last quote on record before the December 2023 delisting; historical, not a current quote)
P/E 12.02 means the share price is 12.02 times one year of earnings per share. Market cap $1.33B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
POINT Biopharma Global Inc. (PNT). POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing radioligands for cancer treatment. The company's lead product candidates target prostate cancer and neuroendocrine tumors, with ongoing Phase III trials.
Last analyzed: Mar 17, 2026POINT Biopharma Global Inc. (PNT) Healthcare & Pipeline Overview
More about this archive record
Can I still buy PNT shares?
No. PNT stopped trading on public markets in December 2023, so the shares are not available through a broker. Anything you see quoted for PNT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PNT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to POINT Biopharma Global Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.